A Study In The Clinical Efficacy And Influencing Factors Of Treatment For Parkinson’s Disease By Umbilical Cord Mesenchymal Stem Cells

Objectives To study the clinical efficacy of human umbilical cord mesenchymal stem cells（hUC-MSCs）transplantation in the treatment of Parkinson’s disease（PD）and the influence factors of efficacy.Methods A total of 34 PD patients admitted to Neurology in the First Hospital of Hebei Medical University were selected as the subjects.The hUC-MSCs isolated from culturewas treated by peripheral vein infusion.Evaluate the symptoms of the PD patients 3 times before treatment,1 months after treatment,and 3 months after treatment by 11scales,including UPDRSⅢ,SCOPA-AUT,MoCA,HAMD₂₄,HAMA₁₄,NPI,VAS,RLSS,PSQI,RBDS,ADL and so on.Statistical analysis of the evaluation results was performed to evaluate the efficacy and influencing factors of hUC-MSCs transplantation for PD patients.Results 1 From the beginning of transplantation to the end of follow-up,34 patients had no obvious anaphylaxis and graft versus host disease.2 SCOPA-AUT and VAS scores were not significantly improved（P>0.05）,and the rest 9 scale scores improved significantly（P<0.05）,at 1 monthafter treatment;There was no significant improvement in SCOPA-AUT score（P>0.05）at three months after treatment,and the other 10 scale scores improved significantly（P<0.05）at three months after treatment.Three months after transplantation,compared with 1 month,there was no significant improvement in 11 scale scores（P>0.05）.3 The improvement of SCOPA-AUT,MoCA and ADL scores in women was more obvious（P<0.05）.The improvement of the RBD symptom scale and the RLS symptom scale in the disease course more than 5 years was more obvious（P<0.05）.At 1 months after treatment,the improvement of the PSQI score in the younger than 65years old group was more obvious（P<0.05）,but there was no significant difference in the improvement of the PSQI score in the two groups at three months after the treatment（P>0.05）.At one months after treatment,the improvement of the MoCA score in no chronic disease group was more obvious（P<0.05）,but there was no significant difference in the improvement of the MoCA score in the two groups at three months after the treatment（P>0.05）.Conclusions 1 hUC-MSCs transplantation by vein graft is safe and effective for PD patients.It can improve MS and most NMS,but it has no obvious improvement on autonomic nervous function symptoms.2 The efficacy of 3 months after transplantation was not significantly better than that of 1 months.3 Gender and disease course have an effect on the curative effect.Women’s efficacy in autonomic nervous symptoms,cognitive function and activities of daily living is more obvious.RBD symptoms and RLS symptoms in patients with more than 5 years disease course are more effective.